Tagged with US

Belgium Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on top of the rapidly evolving technologies being brought forward today, and the significance of a new early access programme for…

USA Sanskriti Thakur of decentralised clinical trial platform provider Medable, writing in the May 2023 edition of DIA’s Global Forum magazine, argues for an urgent rethink of clinical research to better include a more diverse patient population and protect women, mothers, families, and society at large.   This Mother’s Day, women…

Europe In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the Agency’s approach to antimicrobial resistance, and highlights how it hopes to contribute to a stronger European clinical trials ecosystem.  …

USA With a total R&D spend of USD 2.66 billion in 2022 and a pipeline that features cutting-edge technologies such as mRNA, cell therapy and gene editing, Vertex Pharmaceuticals is looking to deliver “serial innovation” by investing most of its resources in research. And while some other biopharma companies depend on…

Opinion Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs in 2023 to combat the “tripledemic” burden of COVID-19, flu and RSV.   2023 will be a pivotal year for…

USA In the current economic environment companies are faced with increased pressure to manage cash and meet investor expectations with tightened budgets. Life science industry CFOs, as a recent survey and webinar reveal, are looking to preserve and generate cash by making their companies more efficient and building partnerships while confronting…

USA After considerable government pressure to reduce insulin costs in the US, Eli Lilly recently slashed its prices by as much as 70 percent, followed by competitors Novo Nordisk and Sanofi. While these steps to make insulin more affordable, together with the US Medicare insulin price cap that came into effect…

Global In the largest pharma acquisition in four years, Pfizer has picked up oncology biotech Seagen for USD 43 billion. The deal, which could signal a rebound in M&A activity as big pharma companies look to renew their pipelines in preparation for post-COVID and off-patent losses, bolsters Pfizer’s continuing push into…

India The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and the Cipla manufacturing site under FDA scrutiny.   Dr. Reddy’s to buy Mayne Pharma’s US business for USD 105 million…

Germany Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19 deaths among patients using its products and other areas of the business were faced with economic headwinds, the group was…

Global Blue Spoon Consulting’s John G. Singer takes aim at the recent anti-Big Pharma rhetoric around the drug pricing crisis in the US, instead calling for a more holistic view of the situation, acknowledging the role being played by pharmacy benefit managers (PBMs). More importantly, Singer sees a new approach to…

USA As debate rages over where to lay the blame for the USA’s drug affordability crisis, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA) sets out a defence of the country’s pharmacy benefit manager (PBM) industry. Payne instead raises concerns with big drug companies’…